Latest news
Trastuzumab Rezetecan Improves Progression-Free Survival in HER2-Positive Metastatic Breast Cancer - The ASCO PostThe ASCO Post · Fri, 07 Aug 2026 14:42:22 GMTHORIZON-Breast01: Trastuzumab Rezetecan Delivers 30.6-Month PFS - OncodailyOncodaily · Wed, 05 Aug 2026 16:39:20 GMTDr Barot on the FDA Approval of Palbociclib/Trastuzumab ± Pertuzumab in HER2+ Breast Cancer - OncLiveOncLive · Fri, 31 Jul 2026 03:40:00 GMT